Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 00:51:47 - browse：16

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Stephen Quake on the Chan Zuckerberg quest to conquer disease

explore

WSS

Late stage cancers on the rise after pandemic delayed screenings

The cancer stories no one wants to hear

Report captures long Covid’s disabling effects and policy challenges

Study: Why relieving medical debt did not improve financial outcomes

Heart disease in astronauts blamed on cosmic radiation

5 takeaways from STAT's examination of Zynex Medical

knowledge

Wikipedia

focus

Jerome Adams on the need for new antivirals for Covid

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Cancer drug shortages should be causing more outrage

The a glaring gap in research on serious mental illness and primary care

ChatGPT in medicine: STAT answers readers' burning questions

Personalized medicine goes far beyond genetics

After affirmative action ruling, medical educators look to 'holistic review'

California wildfire smoke linked to 52,000 early deaths, study says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lilly's Alzheimer's drug donanemab backed by FDA advisers

focus

FDA approves Sage Therapeutics’ rapid

'Null' research findings aren't empty of meaning. Let's publish them

Health care court cases: Humana, Sutter, Novant

The system is set up to fail children with medical complexity

CDC recommends RSV monoclonal antibody for infants

ALS patient reclaims some autonomy thanks to wearable 'robot'

knowledge

explore

explore

hotspot